non-Hodgkin's lymphoma
EC Grants Marketing Authorization to Axicabtagene Ciloleucel for Use in Second-Line DLBCL, HGBL
Leah SherwoodAggressive B-Cell Lymphoma | December 22, 2022
The EC granted marketing authorization to axicabtagene ciloleucel for adult patients with DLBCL and HGBL.
Read More
Advertisement
Advertisement
Advertisement

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    Editorial Board

    About Us

    Terms of Use

    Advertising

    Privacy Policy

    Our Network

    MashupMD

    GU Oncology Now

    Cancer Nursing Today

    Urban Health Today

    DocWire News

    Connect

    eNewsletters

    Calendar of Events

    Contact Us

    Contribute

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |